OCS

Oculis Holding AG (NASDAQ:OCS) is a clinical-stage biopharmaceutical company founded in Switzerland and publicly traded since May 2021. The company is headquartered in Zug, Switzerland, and focuses on developing innovative topical treatments for various eye diseases. As a clinical-stage biotechnology firm, Oculis has no approved products on the market yet and is currently advancing multiple drug candidates through different phases of clinical trials. The company represents a specialized approach to ophthalmology, targeting both front-of-the-eye conditions like dry eye disease and back-of-the-eye disorders such as diabetic macular edema.